enVVeno Medical (enVVeno Medical) Interest Expense : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is enVVeno Medical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. enVVeno Medical's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. enVVeno Medical's Operating Income for the three months ended in Mar. 2024 was $ -5.50 Mil. enVVeno Medical's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate enVVeno Medical's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

enVVeno Medical Interest Expense Historical Data

The historical data trend for enVVeno Medical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

enVVeno Medical Interest Expense Chart

enVVeno Medical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

enVVeno Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

enVVeno Medical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

enVVeno Medical (NAS:NVNO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

enVVeno Medical's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-5.50 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.97 Mil.

enVVeno Medical's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate enVVeno Medical's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. enVVeno Medical Corp has enough cash to cover all of its debt. Its financial situation is stable.

enVVeno Medical (enVVeno Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » enVVeno Medical Corp (NAS:NVNO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

5HJ:Germany 5HJ:Germany

Address

70 Doppler, Irvine, CA, USA, 92618

Website

https://www.envveno.com

enVVeno Medical Corp is a medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).

Executives

Hamed Alavi	officer: Chief Technology Officer	ENVVENO MEDICAL CORPORATION, 70 DOPPLER, IRVINE CA 92618
Francis Duhay	director	HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Sanjay Shrivastava	director	HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert Andrew Berman	director, officer: CEO	C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Matthew Jenusaitis	director	2 GOODYEAR, IRVINE CA 92618
Robert Gray	director	70 DOPPLER, IRVINE CA 92618
Marc H. Glickman	officer: See Remarks	70 DOPPLER, IRVINE CA 92618
Biodyne Holding, S.a.	10 percent owner	13 RUE DE LA GARE, MORGES V8 1110
Craig Glynn	officer: Chief Financial Officer	70 DOPPLER, IRVINE CA 92618
Marcus W. Robins	director	C/O HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert A Rankin	officer: Chief Financial Officer	9200 SUNSET BLVD., SUITE 425, WEST HOLLYWOOD CA 90069
Browston Trading Ltd	10 percent owner	P.O. BOX 20533, NICOSIA G4 1660
Robert W. Doyle	director	70 DOPPLER, IRVINE CA 92618
Robert A. Anderson	director	70 DOPPLER, IRVINE CA 92618
Susan Montoya	officer: See Remarks	70 DOPPLER, IRVINE CA 92618